Clinical Trial Update: Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab combined with Itacitinib (INCB039110) for non-small cell lung cancer was terminated; results posted previously.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Itacitinib (INCB039110) (INCB039110)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Pennsylvania | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-09-13